ArticleClinical and translational allergy2021

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.

Lisha Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.